Opus Point Partners Management, LLC - Q2 2016 holdings

$104 Million is the total value of Opus Point Partners Management, LLC's 43 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was - .

 Value Shares↓ Weighting
IWM NewISHARES TRrussell 2000 etf$22,996,000200,000
+100.0%
22.21%
IBB NewISHARES TRnasdq biotec etf$4,550,00017,681
+100.0%
4.39%
XBI NewSPDR SERIES TRUSTs&p biotech$3,183,00058,857
+100.0%
3.07%
GSK NewGLAXOSMITHKLINE PLCsponsored adr$2,167,00050,000
+100.0%
2.09%
Q NewQUINTILES TRANSNATIO HLDGS I$1,406,00021,520
+100.0%
1.36%
NVAX NewNOVAVAX INC$212,00029,107
+100.0%
0.20%
CPHD NewCEPHEID$209,0006,782
+100.0%
0.20%
LBIO NewLION BIOTECHNOLOGIES INC$196,00024,226
+100.0%
0.19%
GRFS NewGRIFOLS S Asp adr rep b nvt$187,00011,188
+100.0%
0.18%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-08-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
METTLER-TOLEDO INTL CMN20Q3 20194.7%
ALNYLAM PHARMACEUTICALS, INC. CMN20Q3 20195.0%
VERTEX PHARMACEUTICALS INC CMN20Q3 20194.0%
ILLUMINA, INC. CMN20Q3 20194.4%
SEATTLE GENETICS, INC. CMN20Q3 20194.0%
ALEXION PHARMACEUTICALS INC CMN20Q3 20194.3%
INCYTE CORPORATION CMN20Q3 20194.4%
NEKTAR THERAPEUTICS CMN20Q3 20194.9%
REGENERON PHARMACEUTICALS20Q3 20193.8%
CELGENE CORPORATION CMN20Q3 20193.8%

View Opus Point Partners Management, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2019-11-14
13F-HR2019-08-14
13F-HR2019-05-15
13F-HR2019-02-14
13F-HR2018-11-14
13F-HR2018-08-14
13F-HR2018-05-15
13F-HR2018-02-14
13F-HR/A2017-11-17
13F-HR2017-11-14

View Opus Point Partners Management, LLC's complete filings history.

Compare quarters

Export Opus Point Partners Management, LLC's holdings